Ghent University Academic Bibliography

Advanced

Long-term antibody persistence after vaccination with a 2-dose Havrix™ (inactivated hepatitis A vaccine) : 20 years of observed data, and long-term model-based predictions

Heidi Theeten, Koen Van Herck UGent, Olivier Van Der Meeren, Priya Crasta, Pierre Van Damme and Niel Hens (2015) VACCINE. 33(42). p.5723-5727
abstract
Antibody persistence in two cohorts of adults, who received inactivated hepatitis A (HAV) vaccine (1440El.U; Havrix (TM); GSK Vaccines) according to a 0-6 or 0-12 month schedule in 1992-1993, has been measured annually. After 20 years, >97% of the subjects in both studies were seropositive for anti-HAV antibodies. Geometric mean concentrations in the according-to-protocol cohorts were 312 mIU/ml in 34/36 subjects vaccinated initially at 0-6 months (NCT00289757) and 317 mIU/ml in 85/86 subjects vaccinated at 0-12 months (NCT00291876). Over the whole follow-up period, seven subjects (2 + 5, respectively) lost circulating anti-HAV antibodies but mounted a strong response after HAV booster administration (1440El.U). Mathematical modelling, which was applied to assess true persistence at Year 20 (accounting for drop-outs and missing data), and to predict longer-term persistence confirmed previous estimates that seropositive anti-HAV levels would persist in >= 95% vaccinees at Year 30 and >= 90% at Year 40.
Please use this url to cite or link to this publication:
author
organization
alternative title
Long-term antibody persistence after vaccination with a 2-dose Havrix (TM) (inactivated hepatitis A vaccine) : 20 years of observed data, and long-term model-based predictions
year
type
journalArticle (original)
publication status
published
subject
keyword
IMMUNOGENICITY, FOLLOW-UP, ADULTS, Immunogenicity, Inactivated hepatitis A vaccine, Long-term follow-up, Mathematical modelling
journal title
VACCINE
Vaccine
volume
33
issue
42
pages
5723 - 5727
Web of Science type
Article
Web of Science id
000364268500035
JCR category
MEDICINE, RESEARCH & EXPERIMENTAL
JCR impact factor
3.413 (2015)
JCR rank
36/124 (2015)
JCR quartile
2 (2015)
ISSN
0264-410X
DOI
10.1016/j.vaccine.2015.07.008
language
English
UGent publication?
yes
classification
A1
copyright statement
Creative Commons Attribution 4.0 International Public License (CC-BY 4.0)
id
8121830
handle
http://hdl.handle.net/1854/LU-8121830
date created
2016-10-19 17:33:57
date last changed
2017-04-12 11:51:42
@article{8121830,
  abstract     = {Antibody persistence in two cohorts of adults, who received inactivated hepatitis A (HAV) vaccine (1440El.U; Havrix (TM); GSK Vaccines) according to a 0-6 or 0-12 month schedule in 1992-1993, has been measured annually. After 20 years, {\textrangle}97\% of the subjects in both studies were seropositive for anti-HAV antibodies. Geometric mean concentrations in the according-to-protocol cohorts were 312 mIU/ml in 34/36 subjects vaccinated initially at 0-6 months (NCT00289757) and 317 mIU/ml in 85/86 subjects vaccinated at 0-12 months (NCT00291876). Over the whole follow-up period, seven subjects (2 + 5, respectively) lost circulating anti-HAV antibodies but mounted a strong response after HAV booster administration (1440El.U). Mathematical modelling, which was applied to assess true persistence at Year 20 (accounting for drop-outs and missing data), and to predict longer-term persistence confirmed previous estimates that seropositive anti-HAV levels would persist in {\textrangle}= 95\% vaccinees at Year 30 and {\textrangle}= 90\% at Year 40.},
  author       = {Theeten, Heidi and Van Herck, Koen and Van Der Meeren, Olivier and Crasta, Priya and Van Damme, Pierre and Hens, Niel},
  issn         = {0264-410X},
  journal      = {VACCINE},
  keyword      = {IMMUNOGENICITY,FOLLOW-UP,ADULTS,Immunogenicity,Inactivated hepatitis A vaccine,Long-term follow-up,Mathematical modelling},
  language     = {eng},
  number       = {42},
  pages        = {5723--5727},
  title        = {Long-term antibody persistence after vaccination with a 2-dose Havrix{\texttrademark} (inactivated hepatitis A vaccine) : 20 years of observed data, and long-term model-based predictions},
  url          = {http://dx.doi.org/10.1016/j.vaccine.2015.07.008},
  volume       = {33},
  year         = {2015},
}

Chicago
Theeten, Heidi, Koen Van Herck, Olivier Van Der Meeren, Priya Crasta, Pierre Van Damme, and Niel Hens. 2015. “Long-term Antibody Persistence After Vaccination with a 2-dose HavrixTM (inactivated Hepatitis A Vaccine) : 20 Years of Observed Data, and Long-term Model-based Predictions.” Vaccine 33 (42): 5723–5727.
APA
Theeten, Heidi, Van Herck, K., Van Der Meeren, O., Crasta, P., Van Damme, P., & Hens, N. (2015). Long-term antibody persistence after vaccination with a 2-dose HavrixTM (inactivated hepatitis A vaccine) : 20 years of observed data, and long-term model-based predictions. VACCINE, 33(42), 5723–5727.
Vancouver
1.
Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose HavrixTM (inactivated hepatitis A vaccine) : 20 years of observed data, and long-term model-based predictions. VACCINE. 2015;33(42):5723–7.
MLA
Theeten, Heidi, Koen Van Herck, Olivier Van Der Meeren, et al. “Long-term Antibody Persistence After Vaccination with a 2-dose HavrixTM (inactivated Hepatitis A Vaccine) : 20 Years of Observed Data, and Long-term Model-based Predictions.” VACCINE 33.42 (2015): 5723–5727. Print.